Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Conditions
Brief summary
This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older patients with untreated Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Biological therapies, such as brentuximab vedotin, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Nivolumab and brentuximab vedotin may work better in treating older patients with untreated Hodgkin lymphoma.
Detailed description
PRIMARY OBJECTIVE: I. To determine the efficacy based on overall metabolic response rate (partial metabolic response \[PMR\] + complete metabolic remission \[CMR\]) of brentuximab vedotin/nivolumab in previously untreated Hodgkin lymphoma patients 60 years of age or older, or those considered unsuitable for standard chemotherapy because of a low cardiac ejection fraction (\< 50%) or impaired pulmonary or renal function. SECONDARY OBJECTIVES: I. The complete metabolic response (CMR) rate. II. Safety and tolerability of the regimen in this patient population. III. Duration of response (DOR). IV. Progression-free survival (PFS). V. Overall survival (OS). CORRELATIVE RESEARCH OBJECTIVES: I. T-cell/cytokine - peripheral blood specimens will be used to assess T-cell activation and cytokine up regulation as measures of treatment effect. II. Biomarkers - intratumoral cell populations, genetic variability, serum cytokines and T-cell activation will be evaluated to identify potential biomarkers that correlate with response to therapy. OUTLINE: Patients receive brentuximab vedotin intravenously (IV) over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 30 days for 90 days, every 90 days for 2.5 years, and then every 6 months until 5 years from registration.
Interventions
DRUGBrentuximab Vedotin
Given IV
BIOLOGICALNivolumab
Given IV
Sponsors
National Cancer Institute (NCI)
Academic and Community Cancer Research United
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Classical Hodgkin lymphoma determined by local hematopathology review * One of the following: * Age \>= 60 years * Age \< 60 years but unsuitable for standard chemotherapy because of a cardiac ejection fraction of \< 50%, a pulmonary diffusion capacity \< 80%, or a creatinine clearance \>= 30 and \< 60 mL/min, or refused standard chemotherapy despite efforts to convince them otherwise * Requirement for systemic chemotherapy: all stages except IA (not bulky disease), if involved field is considered radiotherapy (RT) curative * Previously untreated with either chemotherapy, radiation therapy or either brentuximab vedotin or nivolumab, or another check point inhibitor * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2 * Absolute neutrophil count (ANC) \>= 1500/mm\^3, unless secondary to bone marrow involvement; obtained =\< 7 days prior to registration * Leukocytes \>= 3,000/mm\^3, obtained =\< 7 days prior to registration * Platelet count \>= 100,000/mm\^3, obtained =\< 7 days prior to registration * Hemoglobin \> 9.0 g/dL - unless determined by treating physician to be disease related, obtained =\< 7 days prior to registration * Total bilirubin =\< 1.5 x upper limit of normal (ULN), obtained =\< 7 days prior to registration * Aspartate aminotransferase (aspartate transaminase \[AST\]) =\< 2.5 x ULN, obtained =\< 7 days prior to registration * Alanine aminotransferase (alanine transaminase \[ALT\]) =\< 2.5 x ULN, obtained =\< 7 days prior to registration * Creatinine =\< 2.0 mg/dL, obtained =\< 7 days prior to registration * Amylase and/or lipase =\< 1.5 x ULN, obtained =\< 7 days prior to registration * Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 24 hours prior to registration * Note: women of child-bearing potential (WOCBP) must use appropriate method(s) of contraception; WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * Note: during the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up * Ability to understand and willingness to sign an informed written consent * Provide blood and tissue samples for mandatory correlative research purposes
Exclusion criteria
* Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Active, known or suspected autoimmune disease; note: subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger * Use of systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications =\< 14 days of registration; Note: Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease * Immunocompromised patients, patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) and currently receiving antiretroviral therapy, patients with a prior history of known or suspected autoimmune disease, active hepatitis B virus surface antigen (HBV sAg+), active hepatitis C (if antibody \[Ab\]+ then polymerase chain reaction \[PCR\]+) indicating acute or chronic infection, and/or history of interstitial lung disease * Allergy to brentuximab vedotin and/or nivolumab * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Have had prior chemotherapy or radiotherapy for Hodgkin lymphoma * Have received either of the study drugs * \< 60 years who are considered candidates for standard chemotherapy * \>= grade 2 peripheral neuropathy * Other active malignancy =\< 2 years prior to registration, unless treated with curative intent; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, they must not be receiving other specific treatment for their cancer * Active central nervous system (CNS) involvement or leptomeningeal metastases involvement * Known history of pancreatitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Metabolic Response Rate | Up to 8 cycles of treatment (approximately 29 weeks) | The primary endpoint of this trial is the rate (percentage) of overall metabolic response. A metabolic response is defined as a participant who has achieved an objective status of Partial metabolic response (PMR) or Complete metabolic response (CMR) at the end of cycle 8. Response is based on PET/CT based on the revised 2014 Lugano Classification. (PMR: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size CMR: Score 1 (no uptake above background), 2 (uptake\<=mediastinum), or 3 (uptake \> mediastinum but \<= liver) with or without a residual mass on PET Deauville 5-Point-Scale. The scale ranges from 1 to 5, where 1 is best and 5 is the worst. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With an Overall Response of Complete Metabolic Response | Up to end of course 8 | The number of participants with an overall response of Complete metabolic response. Response is based on PET/CT based on the revised 2014 Lugano Classification. (CMR: Score 1 (no uptake above background), 2 (uptake\<=mediastinum), or 3 (uptake \> mediastinum but \<= liver) with or without a residual mass on PET Deauville 5-Point-Scale. The scale ranges from 1 to 5, where 1 is best and 5 is the worst. |
| Duration of Response (DOR) | 30 months | DOR is time from the date at which the patient's objective status is first noted to be a CMR or PMR to the earliest date progression (progressive metabolic disease \[PMD\] or progressive disease \[PD\]) is documented. Response is based on PET/CT based on the revised 2014 Lugano Classification. (PMR: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) CMR: Score 1 (no uptake above background), 2 (uptake\<=mediastinum), or 3 (uptake \> mediastinum but \<= liver) with or without a residual mass on PET Deauville 5-Point-Scale. The scale ranges from 1 to 5, where 1 is best and 5 is the worst. PMD: Score 4 or 5 with an increase in intensity of uptake from baseline and/or New FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment PD: An individual node/lesion must be abnormal with: LDi \> 1.5 cm and Increase by ≥ 50% from PPD nadir and, An increase in LDi or SDi from nadir, 0.5 cm for lesions ≤2 cm, 1.0 cm for lesions \> 2 cm) |
| Progression-free Survival | 30 months | Progression-free survival is defined as the time from registration to the earliest date of documentation of disease progression (Progressive metabolic disease (PMD) or Progressive disease (PD)) or death due to any cause. Response is based on PET/CT based on the revised 2014 Lugano Classification. (PMD: Score 4 or 5 with an increase in intensity of uptake from baseline and/or New FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment PD: An individual node/lesion must be abnormal with: LDi \> 1.5 cm and Increase by ≥ 50% from PPD nadir and, An increase in LDi or SDi from nadir, 0.5 cm for lesions ≤2 cm, 1.0 cm for lesions \> 2 cm) |
| Overall Survival | 30 months | The distribution of overall survival will be estimated using the method of Kaplan-Meier. |
| Number of Participants Experiencing at Least One Adverse Events Graded 3 or Higher Deemed at Least Possibly Related to Treatment | Up to 8 cycles of treatment (approximately 29 weeks) | Number of participants experiencing at least one toxicity. Toxicity is defined as an adverse event graded 3 or higher by Common Terminology Criteria for Adverse Events version 4.0 deemed at least possibly related to treatment. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Brentuximab Vedotin, Nivolumab) Patients receive 1.8 mg/kg (cap at 180 mg) in 100 to 250 mL NS to final concentration 0.4 mg/mL to 1.8 mg/mL brentuximab vedotin IV over 30 minutes and 3 mg/kg in 100 cc NS nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. | 46 |
| Total | 46 |
Baseline characteristics
| Characteristic | Treatment (Brentuximab Vedotin, Nivolumab) |
|---|---|
| Age, Continuous | 71.5 years |
| ECOG Performance Status 0 | 14 Participants |
| ECOG Performance Status 1 | 26 Participants |
| ECOG Performance Status 2 | 6 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Race (NIH/OMB) White | 39 Participants |
| Sex: Female, Male Female | 21 Participants |
| Sex: Female, Male Male | 25 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 46 |
| other Total, other adverse events | 46 / 46 |
| serious Total, serious adverse events | 21 / 46 |
Outcome results
Primary
Overall Metabolic Response Rate
The primary endpoint of this trial is the rate (percentage) of overall metabolic response. A metabolic response is defined as a participant who has achieved an objective status of Partial metabolic response (PMR) or Complete metabolic response (CMR) at the end of cycle 8. Response is based on PET/CT based on the revised 2014 Lugano Classification. (PMR: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size CMR: Score 1 (no uptake above background), 2 (uptake\<=mediastinum), or 3 (uptake \> mediastinum but \<= liver) with or without a residual mass on PET Deauville 5-Point-Scale. The scale ranges from 1 to 5, where 1 is best and 5 is the worst.
Time frame: Up to 8 cycles of treatment (approximately 29 weeks)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Brentuximab Vedotin, Nivolumab) | Overall Metabolic Response Rate | 60.9 percentage of participants |
Secondary
Duration of Response (DOR)
DOR is time from the date at which the patient's objective status is first noted to be a CMR or PMR to the earliest date progression (progressive metabolic disease \[PMD\] or progressive disease \[PD\]) is documented. Response is based on PET/CT based on the revised 2014 Lugano Classification. (PMR: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) CMR: Score 1 (no uptake above background), 2 (uptake\<=mediastinum), or 3 (uptake \> mediastinum but \<= liver) with or without a residual mass on PET Deauville 5-Point-Scale. The scale ranges from 1 to 5, where 1 is best and 5 is the worst. PMD: Score 4 or 5 with an increase in intensity of uptake from baseline and/or New FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment PD: An individual node/lesion must be abnormal with: LDi \> 1.5 cm and Increase by ≥ 50% from PPD nadir and, An increase in LDi or SDi from nadir, 0.5 cm for lesions ≤2 cm, 1.0 cm for lesions \> 2 cm)
Time frame: 30 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Brentuximab Vedotin, Nivolumab) | Duration of Response (DOR) | NA months |
Secondary
Number of Participants Experiencing at Least One Adverse Events Graded 3 or Higher Deemed at Least Possibly Related to Treatment
Number of participants experiencing at least one toxicity. Toxicity is defined as an adverse event graded 3 or higher by Common Terminology Criteria for Adverse Events version 4.0 deemed at least possibly related to treatment.
Time frame: Up to 8 cycles of treatment (approximately 29 weeks)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab Vedotin, Nivolumab) | Number of Participants Experiencing at Least One Adverse Events Graded 3 or Higher Deemed at Least Possibly Related to Treatment | 30 Participants |
Secondary
Number of Participants With an Overall Response of Complete Metabolic Response
The number of participants with an overall response of Complete metabolic response. Response is based on PET/CT based on the revised 2014 Lugano Classification. (CMR: Score 1 (no uptake above background), 2 (uptake\<=mediastinum), or 3 (uptake \> mediastinum but \<= liver) with or without a residual mass on PET Deauville 5-Point-Scale. The scale ranges from 1 to 5, where 1 is best and 5 is the worst.
Time frame: Up to end of course 8
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Brentuximab Vedotin, Nivolumab) | Number of Participants With an Overall Response of Complete Metabolic Response | 22 Participants |
Secondary
Overall Survival
The distribution of overall survival will be estimated using the method of Kaplan-Meier.
Time frame: 30 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Brentuximab Vedotin, Nivolumab) | Overall Survival | NA months |
Secondary
Progression-free Survival
Progression-free survival is defined as the time from registration to the earliest date of documentation of disease progression (Progressive metabolic disease (PMD) or Progressive disease (PD)) or death due to any cause. Response is based on PET/CT based on the revised 2014 Lugano Classification. (PMD: Score 4 or 5 with an increase in intensity of uptake from baseline and/or New FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment PD: An individual node/lesion must be abnormal with: LDi \> 1.5 cm and Increase by ≥ 50% from PPD nadir and, An increase in LDi or SDi from nadir, 0.5 cm for lesions ≤2 cm, 1.0 cm for lesions \> 2 cm)
Time frame: 30 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Brentuximab Vedotin, Nivolumab) | Progression-free Survival | 18.3 months |